Health Catalyst Q2 revenue $73.2M beats midpoint; raises FY2023 guidance

Health Catalyst, Inc.

2023-Q2 EPS reported -$1.18 revenue$147,081,000

Total revenue $73.2M (+4% YoY) vs guidance midpoint of $72.3M.
Adjusted EBITDA $3.5M vs guidance midpoint of $2.75M; margin ~5% (+200 bps YoY).
Two large TEMS contracts signed: ~$50M and ~$60M, each with existing health system clients.
FY2023 revenue guidance raised to $290.5M–$295.5M; Adjusted EBITDA raised to $10.0M–$12.0M.
Net loss improved to $32.6M from $33.4M YoY; dollar-based retention reiterated at 102%–110%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Health Catalyst, Inc. reported the quarter ended June 30, 2023 results: revenue $73.2 million. Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $73.2 million
Guidance: raised
Result: reported results

Exact text from the filing

today reported financial results for the quarter ended June 30, 2023. “For the second quarter of 2023, we are encouraged by our financial results, including total revenue of $73.2 million and Adjusted EBITDA of $3.5 million, with these results beating the mid-point of our quarterly guidance on each metric. Additionally, given that we are tracking slightly ahead of

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Health Catalyst, Inc. filing history →

Source: SEC EDGAR

accession 0001636422-23-000095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.